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Background: Endometriosis is a chronic condition whose pathophysiology is unknown, but there is evidence
suggesting a link with oxidative stress. Paraoxonase is a serum enzyme which circulates associated with
high-density lipoprotein (HDL). It acts protecting HDL and LDL of lipid peroxidation. We aimed to compare the
serum levels of PON-1 activity in women with endometriosis in different stages of the disease (minimal/mild and
moderate/severe).
Methods: 80 infertile women with endometriosis diagnosed by laparoscopy/laparotomy with histologic
confirmation of the disease were divided according to the American Society for Reproductive Medicine
classification in minimal/mild (n = 33) and moderate/severe (n = 47) cases. Paraoxonase activity and arilesterase
activity were measured by spectrophotometry. Body mass index and fasting glucose levels were also determined.
Results: The paraoxonase activity were 191.29 ± 22.41 U/l in women with minimal/mild endometriosis and 224.85 ±
21.50 U/l in women with moderate/severe disease (P = 0.274). Considering arilesterase level, the results showed 89.82 ±
4.61 U/l in women with minimal/mild endometriosis and 90.78 ± 3.43 U/l in moderate/severe disease
(P = 0.888).
Conclusions: Evidence of lower paraoxonase activity in women with endometriosis was not found in this study.
Besides, no difference was found considering minimal/mild or moderate/severe endometriosis.
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Endometriosis is a chronic condition characterized by
tissue histologically similar to the endometrium im-
plants, grows and develops outside the uterine cavity
associated with pelvic pain and infertility [1,2]. It affects
3-10% of women in their reproductive years and 20-50%
of women with infertility [3]. The pathophysiologic
mechanism is unknown, but some authors suggest a link
with oxidative stress [4-9]. In the presence of pelvic* Correspondence: bianca.bianco@hotmail.com
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reproduction in any medium, provided the orendometriosis, peritoneal macrophages would be acti-
vated, increasing the production of reactive oxygen species
(ROS) [4], one of the responsible for the inflammatory re-
action observed in endometriosis [6]. Increased levels of
lipid peroxidation markers in peritoneal fluids of women
with endometriosis [10], like tumor necrosis factor (TNF)
α, were found in previous published studies [9].
Those markers are chemotactic factors for monocytes
and T-lymphocytes, such the T-helper, which immune
response has been identified as a main factor in the de-
velopment and progression of endometriosis [5]. An in-
crease in the oxidation of low-density lipoprotein (LDL)
was reported in endometriosis patients [8].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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which circulates associated with HDL (High Density
Lipoprotein) [11-13]. It hydrolyzes various organophos-
phate compounds, including pesticides and neurotoxic
gases. Its name derives from paraoxon, a metabolite of
an ordinary pesticide called parathion, which is hydro-
lyzed by PON1 with modest catalytic efficiency [13]. The
PON1 has an appreciable arylesterase activity, being
phenylacetate the typical substrate. Khersonsky et al.
[14] suggests that PON1 is in fact,a lactonase and not an
esterase or a fosfotriesterase as traditionally described.
PON1 is also involved in the metabolism of drugs, being
used for their inactivation [15]. The identity of the native
substrate of PON1 and other PON’s family enzymes
is not known yet. A possible physiological substrate is
homocysteine-thiolactone, which may be formed from the
non-protein amino acid homocysteine. Serum levels of
homocysteine are known as a risk factor for atherosclerotic
vascular disease by inducing endothelial injury. One of the
potential mechanisms that explain homocysteine’s toxic ef-
fects is homocysteine-thiolactone’s formation, a metabolite
that can modify proteins, including the LDL apoprotein B
and HDL Apo A, favoring atherogenesis [16].
Paraoxonase features two genetic polymorphisms that
results in different paraoxonase activity against the sub-
strate paroxon, particularly when the test is performed
in the presence of NaCl (paraoxonase activity), but not
against the substrate phenylacetate (arilesterase activity)
[12]. Most studies that have attempted to relate the
PON192 polymorphism with diseases, particularly cardio-
vascular disease, were inconclusive.
This enzyme acts protecting HDL and LDL of lipid
peroxidation, degrading cholesterol esters’ oxidized
lipids and phospholipids present in the lipoproteins,
erythrocytes and macrophages. PON1 may otherwise be
inactivated by oxidized lipids [17]. Furthermore, PON1
has additional antiatherogenic properties, as inhibition
of cholesterol biosynthesis by macrophages and stimulat-
ing macrophage cholesterol efflux [18-21]. Paraoxonase
activity measurements have shown an inverse association
with various morbidities, like obesity, cardiovascular dis-
ease, diabetes, metabolic syndrome, and aging, all related
with its antioxidant activity [22-25].
Considering the complex cellular and molecular mecha-
nisms involved in endometriosis formation and progres-
sion, we aimed to compare the serum levels of PON-1
activity in women with endometriosis in different stages of
the disease (minimal/mild and moderate/severe).
Methods
Patients
The studied group consisted of 80 infertile women with
endometriosis attended at Human Reproduction and
Genetics Center of the Faculdade de Medicina do ABC,Santo André, Brazil. Patients with endometriosis-associ-
ated infertility were diagnosed by laparoscopy and classi-
fied according to the American Society for Reproductive
Medicine [26], with histologic confirmation of the disease.
In this group, minimal/mild (stage I and II) endometriosis
was found in 33 cases (41.2%) and moderate/severe (stage
III and IV) endometriosis in 47 cases (58.8%).
The cause of infertility was investigated including a
hormonal and biochemical profile, testing for sexually
transmitted diseases, imaging examinations, investiga-
tion of genetic and/or immunological abnormalities,
hysterosalpingography, hysteroscopy and laparoscopy
(performed in all women up to 36 years of age and also
in patients over 36, whenever there were symptoms or
abnormalities on the imaging examinations), and semen
analysis of the partner. Women with endometriosis who
did not achieve pregnancy after at least twelve natural or
induced cycles following laparoscopy were considered
infertile. Patients with obesity (BMI ≥ 30 kg/m2), smo-
kers and with acute or chronic medical conditions and
whose partner had any male factors associated with in-
fertility were excluded from the study.
Clinical data and peripheral blood samples were col-
lected only after explaining the objectives of the study
and obtaining signed informed consent, as approved by
the local Research Ethics Committee.Laboratory evaluation
5 mL of blood were collected by trained professionals
through a peripheral vein, in a room protected from direct
light. PON activity was determined in blood samples.
The serum was isolated by centrifugation at low speed
(5.000 rpm for 3 minutes) after coagulation. The samples
were stored at −80°C. Paraoxonase activity and arilesterase
activity were determined spectrophotometrically using
paraoxon and phenylacetate as substrates, respectively.
The paraoxonase activity was determined using a PON
paraoxon (diethyl - p-nitrophenyl) as substrate and meas-
uring the increase in absorbance at 412 nm by the forma-
tion of 4 - nitrophenol. The activity was measured at 30°C
during 90 seconds after 12 μl of serum were added to each
well containing 238 μl of Tris/HCl (100 mmol/l, pH 8.0)
buffer containing 2 mmol/l CaCl2 and 5.5 mmol /l of
paraoxon. The regeneration rate of 4-nitrophenol was
measured at 412 nm in a visible plaque spectrophotom-
eter. At the same time the spontaneous hydrolysis of
paraoxon was discounted in a reference well containing
only the buffer with the reagent. The paraoxonase activity
of PON1 was determined in quintuplicate and all results
are expressed in U/ml. The enzyme activity was calculated
by the molar extinction coefficient of 17.100 M-1. cm-1,13
One unit of paraoxonase activity is defined as 1 nmol of 4-
nitrophenol formed per minute. Alternatively paraoxonase
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order to verify the polymorphism increased activity.
PON1’s arilesterase activity in serum was determined
spectrophotometrically by using the synthetic substrate
phenylacetate. The reaction was started by adding 23 ul
of phenylacetate (10 mM) to wells containing 5 ul of
serum (prediluted 1:13) and 222 uL of buffer 50 mmol/l
Tris pH 8.0/1 mmol CaCl2. The production of phenol was
determined spectrophotometrically during 1 minute at
270 nm, using a molar extinction coefficient of 1310/mol/
cm at pH 8.0. The spontaneous hydrolysis of paraoxon was
discounted measuring the absorbance in a well containg
only the buffer and phenylacetate. The PON1’s arilesterase
activity was determined in quintuplicate and all results
were expressed as U/ml. 1U of phenylacetate hydrolyses
1 μmol arilesterase per minute [22-24].
BMI was calculated according to the Quetelet formula,
by dividing the weight in kilogram by the squared height
in metres (kg/m2). The blood glucose level was deter-
mined using commercially available assay kits. The pa-
tients were fasting for at least 8 hours before their blood
were collected for laboratory glucose level evaluation.
Statistical analyses
Statistical analyses were made using Minitab 16 for
Windows [27]. We assumed a significance level of 0.05
for the statistical tests. Normality of data distribution of
women with minimal/mild and moderate/severe endo-
metriosis for both enzymes were verified using the
Anderson-Darling normality test. Differences among the
minimal/mild and moderate/severe endometriosis for
PON1’s paraoxonase and arilesterase activity were
assessed using the Mann–Whitney U test. Correlation
between PON1’s paraoxonase and arilesterase activity
and clinical severity of the disease was performed by
Sperman’s rank test.
Results
The group mean age was 33.5 ± 7.5 years, with a mean
body mass index (BMI) of 24.02 ± 5.88 kg/m2. The mean
fasting glucose levels were 93 ± 26 mg/dl.
The serum PON1’s paraoxonase and arilesterase activ-
ities in each group are presented in Table 1. We did notTable 1 Serum PON1’s paraoxonase and arilesterase
activities in women with minimal/mild and moderate/






PON1’s paraoxonase activity (U/l) 191.29 ± 22.41a 224.85 ± 21.50
PON1’s arilesterase activity (U/l) 89.82 ± 4.61b 90.78 ± 3.43
aP = 0.274 vs women with Moderate/severe endometriosis.
bP = 0.888 vs women with Moderate/severe endometriosis.find any difference in women with minimal/mild and
moderate/severe endometriosis for both enzymes, even
when the patients were analyzed separately according to
endometriosis stage (I, II, III and IV endometriosis).
Discussion
In the present study, we hypothesized a possible relation
between paraoxonase activity and endometriosis develop-
ment. However, we found no difference between the
PON1’s paraoxonase and arilesterase activity comparing the
group with minimal/mild stage disease with the one with
moderate/severe endometriosis. Besides, there was no
correlation with the stage of the disease and PON1’s
activity. Analysis considering the four stages separately was
performed, but it also did not showed positive correlation.
Verit et al. [10] have supposed, previously, the associ-
ation of PON1’s activity and endometriosis. The authors
studied 87 women who underwent laparoscopy or laparot-
omy (40 control patients with no pathologic findings; 24
women with minimal/mild endometriosis and 23 women
with moderate/severe endometriosis). PON-1 activity was
significantly higher in women with moderate/severe endo-
metriosis than in women with minimal/mild disease and
controls, and in women with minimal/mild endometriosis
compared with control groups (P < 0.0001, for all). A sig-
nificant negative correlation was found between PON-1
activity and stage of the disease (r520.74, P < 0.0001). The
authors conclude that PON-1 activity can be used as a
diagnostic test to detect endometriosis.
Although we didn’t have a control group, the average
activity of the enzyme we found in this study was not
very different from the activity found by other studies in
women without endometriosis (183.7 ± 22.3 U/l in 40
women with no endometriosis in the study of Verit
et al., 2008 [10]; 258.29 ± 101.95 U/l in 22 adult females
with no endocrine or metabolic disorders or history of
drug use in the study of Ozenoglu et al., 2008 [28]; and
240 ± 144 U/l in 200 individual, both men and women,
from blood bank serum samples in a study performed by
Davis et al., 2009 [29]). Besides, in our study the patients
were diagnosed with endometriosis by laparoscopy/
laparotomy, and classified according to the American
Society for Reproductive Medicine [26] with histological
confirmation of the disease, which gives a more accu-
rate diagnosis of the stage of the endometriosis in com-
parison with visual confirmation alone. Barbosa et al.
(2009) [2] observed endometriosis in healthy peritoneum
biopsy of fertile and asymptomatic women, showing the
importance of histological confirmation for minimal/
mild endometriosis.
Studies involving PON1 have attributed an antioxidant
and ateroprotector role to it. They have demonstrated
that reduced paraoxonase activity are observed in adults
with various diseases such as diabetes mellitus, renal
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Others have shown an increased activity of PON1 in
individuals who maintains a physical activity routine,
which is a protective factor against cardiovascular dis-
ease by improving the quality of their HDL [11,33].
However, there is no clear evidence that women with
endometriosis have more atherosclerosis than the gen-
eral population [34,35].
Despite the evidence that oxidative stress may play a
role in endometriosis [4-9], there are other theories that
may explain the pathophysiology of this disease. The
implantation theory proposes that the retrograde
menstruation may result in implantation and growth of
endometrial cavity. The coelomic metaplasia suggests that
there’s a transformation of peritoneal in mullerian cells,
activated by hormones. Combining the two previous the-
ories, the induction theory attributes to immunological
and endogenous biochemical factors the induction of the
differentiation of undifferentiated cells into endometrial
tissue. Finally, recent studies have shown genetic predis-
position and familial tendency of endometriosis. None of
these theories alone have succeeded to determine the
mechanism of the disease [25].
Some authors have also suggested the possibility of
endometriosis is a disease caused or associated with
oxidative stress [36-40]. In the presence of pelvic endo-
metriosis, there was activation of macrophages in the peri-
toneal cavity, which could promote increased production
of reactive oxygen species and nitrogen and, consequently,
oxidative stress, resulting in lipid peroxidation, its degrad-
ation products and the products formed by its interaction
with low-density lipoproteins and other proteins [41]. Oxi-
dized lipids, to decompose, generate products such as
malondialdehyde and could be recognized as foreign, anti-
genic response with consequent triggering antibody pro-
duction. This process leads to oxidative damage to red
blood cells, and peritoneal endometrial cells which, in
turn, stimulate the recruitment and activation of mono-
nuclear phagocytes further perpetuating oxidative damage
in the pelvic cavity. Oxidative stress also damages meso-
thelial cells and can induce the appearance of adhesion
sites for endometrial cells, favoring the development and
progression of endometriosis [40,42].
Although there is evidence suggesting the presence of
oxidative stress in the sites of pelvic endometrial implants,
little is known about the systemic oxidative status in
women with infertility related to endometriosis. Likewise,
very little is known about the association between disease
stage and systemic markers of oxidative stress [40].
The human biological aging is a phenomenon that is
associated with changes in the activity of cells, tissues
and organs, as well as reducing the effectiveness of a set
of processes physiological. With respect to aspects of the
endogenous production of oxidants, both the causes andthe molecular mechanisms involved this process is not
yet sufficiently known. However, evidences attributed to
aging palatine accumulation of structural and functional
changes in macromolecules and cell membranes, caused
by the deleterious effects of free radicals and other react-
ive oxygen species which form spontaneously in the
mitochondria as a consequence of oxidative metabolism
[43]. Thus, one of the possible causes of no association
between PON activity and endometriosis can also be
attributed to the younger age of the patients.
Furthermore, PON’s activity varies widely between indi-
viduals, partly related to polymorphisms present in popula-
tion [23,44,45] and to serum HDL’s level, as HDL is
pointed as the responsible to distribute PON to the tissues,
where it could exercise its antioxidant function [46-49].
Because of those difficulties in comparing PON’s activ-
ity between individuals, we suggest that perhaps a better
way of determining the influence of this enzyme in
endometriosis in further studies is correlating the same
individual PON’s activity along the time, with the evolu-
tion of the disease and response to treatments, corrected
by the patient HDL levels.
In conclusion, evidence of lower paraoxonase activity
in women with endometriosis was not found in the
present study. Besides, no difference was found consid-
ering minimal/mild or moderate/severe endometriosis.
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